68Ga-FAPIs在非肿瘤性疾病中的应用及研究进展  

Application and research progress of 68Ga-FAPIs in non-neoplastic diseases

作　　者：李康 蔡晓雨 边艳珠[1] Li Kang;Cai Xiaoyu;Bian Yanzhu(Department of Nuclear Medicine,Hebei General Hospital,Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders,Shijiazhuang 050051,China)

机构地区：[1]河北省人民医院核医学科、河北省脑网络与认知障碍疾病重点实验室,石家庄050051

出　　处：《中华核医学与分子影像杂志》2024年第7期431-435,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：成纤维细胞激活蛋白(FAP)不仅在大部分肿瘤性疾病的肿瘤相关性成纤维细胞(CAFs)中存在特异性表达,在部分以组织重塑为特征的疾病中也存在高表达。FAP抑制剂(FAPIs)PET显像能靶向显示FAP在组织器官中的分布。目前,68Ga-FAPIs在多种恶性肿瘤探查、诊断、精准分期、靶向治疗以及临床管理中有着重要价值,在多种非肿瘤性疾病的临床诊疗中亦逐渐展现出独特价值和巨大潜力。该文对68Ga-FAPIs在心脏显像、免疫球蛋白(Ig)G4相关性疾病、纤维化、骨关节病等多种非肿瘤性疾病中的应用及研究进展进行综述。Fibroblast activation protein(FAP)is not only specifically expressed in cancer-associated fibroblasts(CAFs)of most neoplastic diseases,but also highly expressed in some diseases characterized by tissue remodeling.FAP inhibitors(FAPIs)PET can target the distribution of FAP in tissues and organs.Currently,68Ga-FAPIs have played essential roles in the exploration,diagnosis,precise staging,targeted therapy,and clinical management of various malignant tumors.And 68Ga-FAPIs PET has shown the unique value and great potential in diagnosing and treating non-neoplastic diseases.This article aims to review the application and research progress of 68Ga-FAPIs in various non-neoplastic diseases such as cardiac imaging,immunoglobulin(Ig)G4-related disease,fibrosis,osteoarthropathy,and so on.

关 键 词：喹啉类 镓放射性同位素 发展趋势 

分 类 号：R817.4[医药卫生—影像医学与核医学]